Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan B Sandler

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Seminars in Respiratory and Critical Care Medicine|August 10, 2005
Epidermal growth factor receptor inhibitors in lung cancer therapyJanessa J Laskin, Alan B Sandler
Cancer Treatment Reviews|February 10, 2004
Epidermal growth factor receptor: a promising target in solid tumoursJanessa J Laskin, Alan B Sandler
Clinical Lung Cancer|January 11, 2005
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomesL Minerva Burgos Fuster, Alan B Sandler
Seminars in Oncology|July 1, 2005
Redefining bronchioloalveolar carcinomaJanessa J Laskin, Alan B Sandler, David H Johnson
Clinical Lung Cancer|March 18, 2009
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapyRoy S Herbst, Thomas J Lynch, Alan B Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancerAlan B Sandler, David H Johnson, Roy S Herbst
American Journal of Clinical Oncology|August 2, 2002
Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignanciesNasser H Hanna, Michael S Gordon, Karen Fife, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
The rationale for adjuvant chemotherapy in stage I non-small cell lung cancerLeora Horn, Alan B Sandler, Joe B Putnam, et al.
Investigational New Drugs|July 12, 2008
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancerHedy Lee Kindler, Howard A Burris, Alan B Sandler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group StudyAfshin Dowlati, Robert Gray, Alan B Sandler, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Seminars in Respiratory and Critical Care Medicine|August 10, 2005
Epidermal growth factor receptor inhibitors in lung cancer therapyJanessa J Laskin, Alan B Sandler
Cancer Treatment Reviews|February 10, 2004
Epidermal growth factor receptor: a promising target in solid tumoursJanessa J Laskin, Alan B Sandler
Clinical Lung Cancer|January 11, 2005
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomesL Minerva Burgos Fuster, Alan B Sandler
Seminars in Oncology|July 1, 2005
Redefining bronchioloalveolar carcinomaJanessa J Laskin, Alan B Sandler, David H Johnson
Clinical Lung Cancer|March 18, 2009
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapyRoy S Herbst, Thomas J Lynch, Alan B Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancerAlan B Sandler, David H Johnson, Roy S Herbst
American Journal of Clinical Oncology|August 2, 2002
Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignanciesNasser H Hanna, Michael S Gordon, Karen Fife, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
The rationale for adjuvant chemotherapy in stage I non-small cell lung cancerLeora Horn, Alan B Sandler, Joe B Putnam, et al.
Investigational New Drugs|July 12, 2008
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancerHedy Lee Kindler, Howard A Burris, Alan B Sandler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group StudyAfshin Dowlati, Robert Gray, Alan B Sandler, et al.
Pageof 7